Press Releases

Date Title and Summary Additional Formats
Toggle Summary /C O R R E C T I O N -- Biocept, Inc./
In the news release, Clinical Results Demonstrating the Performance of Biocept's Target Selector Platform to be Presented at the 2016 European Society of Medical Oncology Annual Congress, issued 29-Sep-2016 by Biocept, Inc. over PR Newswire, we are advised by the company that the first paragraph,
View HTML
Toggle Summary Biocept Added to the Russell Microcap Index
SAN DIEGO , June 26, 2017 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that is has been added to the Russell Microcap®
View HTML
Toggle Summary Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs)
Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) Biocept, Inc. today reported that its scientists and academic collaborators will present a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago,
View HTML
Toggle Summary Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs) San Diego, CA ? Biocept, Inc. today reported that its scientists and academic collaborators will present three posters at the 34th annual San Antonio Breast Cancer
View HTML
Toggle Summary Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Testing for Small Cell Lung Cancer to Patients with Lambert Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals to make Biocept's Target Selector™ test available to LEMS patients in Phase III Firdapse® trial to screen for cancer every six months for up to two years, at no cost to patients
View HTML
Toggle Summary Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 status in Breast Cancer Patients
Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 status in Breast Cancer Patients San Diego, California: ? Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)
View HTML
Toggle Summary Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment
Companies to Evaluate Expression and Mutation in NSCLC Therapeutic Target ALK
View HTML
Toggle Summary Biocept and Insight Genetics to Present ALK Expression Study Data on Liquid Biopsy Platform at the IASLC World Conference on Lung Cancer
Detection of ALK biomarker expression in circulating tumor cells could provide a new method to identify and monitor patients with ALK+ lung cancer SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers in liquid biopsies
View HTML
Toggle Summary Biocept and MediNcrease Health Plans Announce Provider Agreement Expanding Access to Liquid Biopsy Testing
SAN DIEGO and ST. PETERSBURG, Fla. , June 21, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, and MediNcrease Health Plans, LLC
View HTML
Toggle Summary Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States
MLS to market Biocept's proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future
View HTML